Corporate announcement: COVID-19 update
In light of the novel coronavirus (COVID-19) pandemic, as a pharmaceutical company present in 12 European countries, it is a Neuraxpharm priority and responsibility to protect the wellbeing and safety of our employees.
At the same time, we have the fundamental role in regard to the community and the healthcare professionals to guarantee the supply of medicines addressed to patients with a disorder related to the central nervous system (CNS).
At Neuraxpharm, we will continue serving our patients and customers by working remotely where possible, while ensuring a continuous manufacturing of our products under increased safety precautions to maintain our supply via pharmacies and hospitals.
We thank our professionals who continue working in the production sites and laboratories for their commitment.
At Neuraxpharm, we are taking the necessary precautions, and we are monitoring the situation closely as it develops.